# Research Findings for Juakali Hub Enhancement

## 1. Genomics Analysis Framework

### Sequence Analysis
- **Variant Calling**: Process of identifying genetic variants (SNPs, indels) from next-generation sequencing (NGS) data
- **Key Methodologies**:
  - Whole Genome Sequencing (WGS)
  - Whole Exome Sequencing (WES)
  - Targeted sequencing
  - Somatic mutation detection
- **Data Sources**: FASTQ files from sequencing platforms (Illumina NovaSeq, etc.)
- **Output**: Variant annotation with functional impact prediction

### Genetic Screening
- **Purpose**: Identify individuals at higher risk of developing particular disorders or carrying specific genes
- **Risk Classification**:
  - Average risk (general population)
  - Increased/Moderate risk
  - High risk (strong family history)
- **Applications**: Hereditary cancer assessment, inherited disease detection, personalized health recommendations
- **Standards**: Evidence-based clinical trial validation and protocol review

### Protein Folding & Structure Prediction
- **AlphaFold Technology**: AI system developed by Google DeepMind
  - Predicts 3D protein structure from amino acid sequence
  - Achieves >90% accuracy on most proteins
  - Enables understanding of protein-protein interactions
- **Applications**: Drug design, molecular docking, binding affinity prediction
- **Data**: Protein sequences → 3D structure coordinates

## 2. Pan-Cancer Analysis Framework

### TCGA (The Cancer Genome Atlas)
- **Scope**: 20,000+ primary cancer samples across 33 cancer types
- **Data Types**: Genomic, epigenomic, transcriptomic, proteomic (2.5 petabytes)
- **Key Analyses**:
  - Cell-of-origin patterns
  - Oncogenic processes
  - Signaling pathways
  - Cross-cancer mutation patterns
  - Tumor Mutational Burden (TMB) variation across cancer types

### Cross-Cancer Integration
- **Methodology**: Harmonization of multi-institution sequencing data
- **Key Metrics**:
  - Somatic mutations
  - Copy number variations
  - Gene expression profiles
  - DNA methylation patterns
- **Clinical Application**: Identify shared vulnerabilities across cancer types for targeted therapy

### Cancer Types Covered
- Lung adenocarcinoma (TMB-H: 28.9%)
- Bile duct cancer (TMB-H: 10.4%)
- Gastric cancer (TMB-H: 10.1%)
- Esophageal cancer
- And 29 other cancer types

## 3. Medos Agent

### Overview
- **Type**: AI-XR-Cobot system for clinical decision support
- **Architecture**: Combines smart glasses, robotic arms, and multi-agent AI
- **Purpose**: Real-time clinical co-pilot for doctors and nurses
- **Capability**: Enables diagnostic precision comparable to attending physicians

### Clinical Applications
- Real-time clinical decision support
- Treatment planning assistance
- Tertiary care coordination
- Multi-disciplinary case analysis

### Integration Points
- Electronic health records (EHR) access
- Patient data management
- Clinical workflow integration
- Real-time collaboration features

## 4. Cross-Agent Data Sharing Requirements

### Data Flow Architecture
1. **Genomics Module** → Sequence analysis, genetic screening, protein folding results
2. **Shared Analysis Layer** → Pan-cancer mutation profiles, risk assessments
3. **Other Agents** → NurseAI, Clinical Validator, OncoAI consume integrated results

### Real-Time Sync Mechanism
- Event-driven updates when genomics analysis completes
- Shared database tables for mutation data, cancer profiles, risk scores
- WebSocket or polling for real-time updates

### Data Types to Share
- Mutation profiles (SNPs, indels, copy number variations)
- Protein structure predictions
- Cancer risk assessments
- Treatment recommendations
- Drug-gene interactions

## 5. Implementation Priorities

### Phase 1: Database Schema
- Credits and payment tracking
- Agent usage logs
- Genomics data storage (mutations, proteins, cancer profiles)
- Cross-agent sync tables
- Analytics aggregation tables

### Phase 2: Medos Integration
- Add to pageMapping.ts with real metadata
- Create tertiary.html content structure
- Link to clinical decision support workflows

### Phase 3: Mpesa Daraja Integration
- OAuth token generation
- STK Push initiation
- Webhook callback handling
- Payment confirmation and credit allocation

### Phase 4: Analytics Dashboard
- Per-user statistics (agents used, credits spent, payment history)
- Admin platform analytics
- Usage trends and patterns

### Phase 5: Genomics Module
- Sequence analysis with variant calling
- Genetic screening with risk assessment
- Protein folding with structure prediction
- Pan-cancer analysis engine
- Cross-agent sync layer

## 6. External Data Sources

### Genomics Data
- NCBI/NIH databases (variant databases, protein structures)
- TCGA Data Commons (cancer genomics)
- AlphaFold Database (protein structures)
- ClinVar (clinical significance of variants)

### Medical References
- NIH/NCI publications
- PubMed Central research articles
- Clinical trial databases
- Healthcare standards (HL7, FHIR)

### Cancer Databases
- GDC Data Portal (Genomic Data Commons)
- COSMIC (Catalogue of Somatic Mutations in Cancer)
- OncoKB (cancer gene database)
- CIViC (clinical interpretation of variants)
